D.A. Davidson & Co’s Sarepta Therapeutics SRPT Stock Holding History

D.A. Davidson & Co’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,383	Closed	-$219K	–	1438
2024 Q2	$219K	Buy	+1,383	New	+$178K	﹤0.01%	1259
2024 Q1	–	Sell	-2,383	Closed	-$230K	–	1459
2023 Q4	$230K	Hold	2,383	–	–	﹤0.01%	1201
2023 Q3	$289K	Hold	2,383	–	–	﹤0.01%	1100
2023 Q2	$273K	Buy	2,383 +100	+4%	+$12.9K	﹤0.01%	1135
2023 Q1	$315K	Hold	2,283	–	–	﹤0.01%	1061
2022 Q4	$296K	Sell	2,283 -33	-1%	-$3.82K	﹤0.01%	1045
2022 Q3	$256K	Buy	+2,316	New	+$233K	﹤0.01%	1068
2015 Q3	–	Sell	-46	Closed	-$1K	–	2285
2015 Q2	$1K	Sell	46 -701	-94%	-$14.3K	﹤0.01%	2167
2015 Q1	$9K	Buy	747 +46	+7%	+$613	﹤0.01%	1824
2014 Q4	$10K	Hold	701	–	–	﹤0.01%	1821
2014 Q3	$14K	Sell	701 -25	-3%	-$564	﹤0.01%	1762
2014 Q2	$21K	Sell	726 -465	-39%	-$14.7K	﹤0.01%	1642
2014 Q1	$28K	Buy	+1,191	New	+$30.4K	﹤0.01%	1563

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

D.A. Davidson & Co's SRPT Position: Q3 2024 in Review

D.A. Davidson & Co sold out of Sarepta Therapeutics (SRPT) in Q3 2024, closing a stake of 1,383 shares — an estimated $219K sold.

D.A. Davidson & Co first reported a position in SRPT in Q1 2014 and held it in 13 quarters. The position peaked at $315K in Q1 2023. 457 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

D.A. Davidson & Co reported no remaining Sarepta Therapeutics position as of Q3 2024 after selling out during the quarter.
D.A. Davidson & Co sold 1,383 Sarepta Therapeutics shares in Q3 2024, an estimated $219K.
D.A. Davidson & Co first reported a position in Sarepta Therapeutics in Q1 2014 and held it in 13 quarters.
D.A. Davidson & Co's Sarepta Therapeutics position peaked at $315K in Q1 2023.
457 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on D.A. Davidson & Co's 13F filing for Q3 2024, filed 13 Nov 2024.